General Information
Revision date
2018-03-20
Product name
Atovaquone Oral Suspension USP
1.2.1 Relevant identified uses
Atovaquone Oral Suspension USP 750 mg/5 mL
Manufacturer Name
Lupin Limited
Icons in SDS
Company Information
company name
Lupin Limited
Section 2
SECTION 2: Hazards identification
Fire and Explosion Expected to be non-combustible Health Atovaquone oral suspension is contraindicated in patients who develop or have a history of hypersensitivity reactions (e.g., angioedema, bronchospasm, throat tightness, urticaria) to atovaquone or any of the components of atovaquone oral suspension.
Environmental hazards
No information is available about the potential of this product to produce adverse environmental effects.
